219 related articles for article (PubMed ID: 26662954)
61. [Expression of melanoma antigen gene in urinary transitional cell carcinomas].
Geng L; Yu LZ; Du P; Ma M; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 May; 43(10):667-71. PubMed ID: 16008943
[TBL] [Abstract][Full Text] [Related]
62. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
63. The role of TP53 PRO47SER and ARG72PRO single nucleotide polymorphisms in the susceptibility to bladder cancer.
Santos LE; Guilhen AC; de Andrade RA; Sumi LG; Ward LS
Urol Oncol; 2011; 29(3):291-4. PubMed ID: 19523860
[TBL] [Abstract][Full Text] [Related]
64. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.
Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M
Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429
[TBL] [Abstract][Full Text] [Related]
65. Association of hOGG1 and XPD polymorphisms with urothelial carcinoma in Taiwan.
Wang YH; Yeh SD; Shen KH; Shen CH; Tung MC; Liu CT; Chiou HY
Anticancer Res; 2011 Nov; 31(11):3939-44. PubMed ID: 22110223
[TBL] [Abstract][Full Text] [Related]
66. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan.
Chang CH; Yang CM; Yang AH
Cancer; 2007 Apr; 109(8):1487-92. PubMed ID: 17330839
[TBL] [Abstract][Full Text] [Related]
67. Lack of association between HLA-E polymorphisms and transitional cell carcinoma of the bladder.
Veiga-Castelli LC; de Paula Cruz AS; Inácio MM; Mendes-Junior CT; Vianello-Brondani R; Moreau P; Castelli EC; Donadi EA
Tissue Antigens; 2013 Sep; 82(3):197-200. PubMed ID: 23786553
[No Abstract] [Full Text] [Related]
68. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
Tasci AI; Tugcu V; Ozbek E; Ozbay B; Simsek A; Koksal V
BJU Int; 2008 Feb; 101(4):503-7. PubMed ID: 17986285
[TBL] [Abstract][Full Text] [Related]
69. Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract.
Vikram R; Sandler CM; Ng CS
AJR Am J Roentgenol; 2009 Jun; 192(6):1481-7. PubMed ID: 19457808
[TBL] [Abstract][Full Text] [Related]
70. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
71. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
72. Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours.
Yates DR; Rouprêt M; Drouin SJ; Audouin M; Cancel-Tassin G; Comperat E; Bitker MO; Cussenot O
World J Urol; 2013 Feb; 31(1):53-9. PubMed ID: 23053209
[TBL] [Abstract][Full Text] [Related]
73. Association of Caspase-8 Genotypes With Bladder Cancer Risk.
Chen M; Tsai YT; Chang WS; Shih LC; Shen TC; Lin ML; Chao CY; Wang YC; Tsai CW; Bau DT
Anticancer Res; 2019 Sep; 39(9):4767-4773. PubMed ID: 31519577
[TBL] [Abstract][Full Text] [Related]
74. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
75. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
76. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells.
Kuncová J; Urban M; Mandys V
APMIS; 2007 Nov; 115(11):1194-205. PubMed ID: 18092951
[TBL] [Abstract][Full Text] [Related]
77. Significant association of Ku80 single nucleotide polymorphisms with bladder cancer susceptibility in Taiwan.
Chang CH; Chiu CF; Liang SY; Wu HC; Chang CL; Tsai CW; Wang HC; Lee HZ; Bau DT
Anticancer Res; 2009 Apr; 29(4):1275-9. PubMed ID: 19414375
[TBL] [Abstract][Full Text] [Related]
78. Chromosomal aberrations in transitional cell carcinoma: its correlation with tumor behavior.
Yu DS; Chen HI; Chang SY
Urol Int; 2002; 69(2):129-35. PubMed ID: 12187044
[TBL] [Abstract][Full Text] [Related]
79. Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study.
Makboul R; Refaiy AE; Badary FA; Abdelkawi IF; Merseburger AS; Mohammed RA
Korean J Urol; 2015 Jan; 56(1):31-40. PubMed ID: 25598934
[TBL] [Abstract][Full Text] [Related]
80. Interleukin-10 G-1082A and C-819T polymorphisms as possible molecular markers of urothelial bladder cancer.
Ahirwar D; Mandhani A; Mittal RD
Arch Med Res; 2009 Feb; 40(2):97-102. PubMed ID: 19237018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
